Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer

被引：136
作者：
Hironaka S. [1 ]
Zenda S. [1 ]
Boku N. [1 ]
Fukutomi A. [1 ]
Yoshino T. [1 ]
Onozawa Y. [1 ]
机构：
[1] Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, 1007 Shimonagakubo, Nagaizumi-cho
来源：
Gastric Cancer | 2006年 / 9卷 / 1期
关键词：
Gastric cancer; Second-line chemotherapy; Weekly paclitaxel;
D O I：
10.1007/s10120-005-0351-6
中图分类号：
学科分类号：
摘要：
Background. Paclitaxel scheduled every 3 weeks has shown a response rate of ∼20% for gastric cancer, with modest hematological toxicity. Weekly administration of paclitaxel in patients with breast or ovarian cancer has shown equivalent efficacy and milder toxicity compared with an every-3 week schedule. We investigated, retrospectively, the antitumor effects and toxicity profiles of weekly paclitaxel for patients with metastatic or recurrent gastric cancer in clinical practice. Methods. In 38 patients who had metastatic or recurrent histologically confirmed gastric cancer and a history of one prior chemotherapy regimen, other than paclitaxel or docetaxel, paclitaxel (8mg/m2) was administered weekly, three times every 4 weeks, with short-term premedication. Results. All 38 patients had had prior chemotherapy that included 5-fluorouracil, the fluoropyrimidine anticancer drug S-1, or cisplatin. The median number of courses in the present regimen was 6 (range, 1-44+). Dose intensity was 5mg/m2 per week, corresponding to 92% of the planned dose (6mg/m2 per week). The overall response rate was 24% (6/25) in measurable lesions, and pleural effusion and ascites disappeared in 2 of 7 patients (29%) and in 3 of 21 patients (14%), respectively. Median survival time was 151 days from the commencement of this treatment, with a median follow-up period of 260 days. Grade 3 or 4 leukopenia and neutropenia were observed in 11 (29%) and 12 (32%) patients, respectively. Seven patients (18%) died within 30 days of the last administration of paclitaxel. Conclusion. Weekly paclitaxel seems to be active as second-line chemotherapy against metastatic and recurrent gastric cancer. Further study is needed to confirm the efficacy and safety of weekly paclitaxel. © 2006 by International and Japanese Gastric Cancer Association.
引用
收藏
页码：14 / 18
页数：4
相关论文
共 17 条
[11]  
Cho H., Shotsu A., Konishi K., Kanari M., Tsuburaya A., Kobayashi O., Et al., Weekly paclitaxel for the second-line treatment of recurrent and advanced cancer (RAGC), Proc Am Soc Clin Oncol, 21, (2002)
[12]  
Gehan E.A., Tefft M.C., Will there be resistance to the RECIST (Response evaluation criteria in solid tumors)?, J Natl Cancer Inst, 92, pp. 179-81, (2000)
[13]  
Ohtsu A., Shimada Y., Shirao K., Boku N., Hyodo I., Saito H., Et al., Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205), J Clin Oncol, 21, pp. 54-9, (2003)
[14]  
Boku N., Ohtsu A., Shimada Y., Shirao K., Seki S., Saito H., Et al., Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer, J Clin Oncol, 17, pp. 319-23, (1999)
[15]  
Sakata Y., Ohtsu A., Horikoshi N., Sugimachi K., Mitachi Y., Taguchi T., Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (M tegafur-0.M gimestat-M otastat potassium) in advanced gastric cancer patients, Eur J Cancer, 34, pp. 1715-20, (1998)
[16]  
Koizumi W., Kurihara M., Nakano S., Hasegawa K., Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. for the S-1 Cooperative Gastric Cancer Study Group, Oncology, 58, pp. 191-7, (2000)
[17]  
Sugimachi K., Maehara Y., Horikoshi N., Shimada Y., Sakata Y., Mitachi Y., Et al., An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. the S-1 Gastrointestinal Cancer Study Group, Oncology, 57, pp. 202-10, (1999)
12